Title:Design, Synthesis and Biopharmacological Profile Evaluation of New 2-((4- Chlorophenoxy)Methyl)-N-(Arylcarbamothioyl)Benzamides with Broad Spectrum Antifungal Activity
Volume: 23
Issue: 12
Author(s): Carmen Limban, Lia M. Diţu*, Luminița Măruțescu, Alexandru V. Missir, Mariana C. Chifiriuc, Miron T. Căproiu, Laurenţiu Morusciag, Cornel Chiriţă, Ana-Maria Udrea, Diana C. Nuţă and Speranta Avram
Affiliation:
- Department of Botanic- Microbiology, Faculty of Biology, University of Bucharest, Research Institute of University of Bucharest- ICUB, Spl. Independentei no. 91-95, Bucharest,Romania
Keywords:
New benzamides, NMR spectra, yeasts, filamentous fungi, minimal inhibitory concentration, SAR, predicted ADMET.
Abstract: The emerging antifungal resistance represents a major challenge for the treatment
of severe fungal infections, highlighting the need to develop novel and efficient antifungal
compounds. This study aimed to synthesize new title compounds and screen them
for their antifungal activity in order to generate highly accurate structure - activity relationships
of 2-((4-chlorophenoxy)methyl)-N-(arylcarbamothioyl)benzamides and their de novo
derivatives and to unveil some of their mechanisms of action by flow cytometry and fluorescence
microscopy. The presence of functional groups was confirmed for nine new 2-((4-
chlorophenoxy) methyl)-N-(arylcarbamothioyl)benzamides, using experimental and in silico
methods. The antifungal activity was assessed against a broad spectrum of 26 yeast and
filamentous fungal strains, using qualitative and quantitative assays. The results showed
that Candida kefyr has been the most susceptible to all tested compounds, while 1b and 1f induced a strong inhibitory
effect on the filamentous fungi Alternaria rubi, Aspergillus ochraceus and A. niger strains growth. The
derivative 1c in subinhibitory concentrations alsoincreased the susceptibility of Candida albicans clinical
strains to azoles. Predicted drug likeness and pharmacokinetics profiles of most active compounds were compared
with the standard antifungal ketoconazole. Furthermore, the potentially more potent 1c and 1f derivatives
were designed and studied regarding the chemical structure-biological activity relationship and pharmacokinetics
profiles versus ketoconazole. The study confirms that the new benzamide derivatives exhibited an improved
pharmacokinetics profile and a good antifungal activity, acting at least by increasing membrane permeability of
fungal cells. Our results are recommending them as promising candidates for the development of novel therapeutic
alternatives.